PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.13%
EBIT growth 1.25-1.5x TRAW's 34.39%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
37.34%
Operating income growth similar to TRAW's 34.39%. Walter Schloss would assume both share comparable operational structures.
47.13%
Net income growth 1.25-1.5x TRAW's 34.42%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
50.90%
EPS growth 1.25-1.5x TRAW's 36.95%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
52.86%
Diluted EPS growth 1.25-1.5x TRAW's 36.95%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
7.67%
Share count expansion well above TRAW's 4.02%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
12.32%
Diluted share count expanding well above TRAW's 4.02%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
33.57%
OCF growth above 1.5x TRAW's 7.10%. David Dodd would confirm a clear edge in underlying cash generation.
33.08%
FCF growth above 1.5x TRAW's 7.10%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9761.92%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-7404.36%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-3986.05%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-11268.60%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-11424.82%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
97.34%
Positive short-term CAGR while TRAW is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
7616.79%
Equity/share CAGR of 7616.79% while TRAW is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
547.30%
Equity/share CAGR of 547.30% while TRAW is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.66%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-26.31%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-49.44%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.